User profiles for Pavlina Chuntova
 | Pavlina ChuntovaResearch Specialist, UCSF Verified email at ucsf.edu Cited by 771 |
Unique challenges for glioblastoma immunotherapy—discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report …
Cancer immunotherapy has made remarkable advances with over 50 separate Food and
Drug Administration (FDA) approvals as first- or second-line indications since 2015. These …
Drug Administration (FDA) approvals as first- or second-line indications since 2015. These …
[HTML][HTML] Macrophages: regulators of the inflammatory microenvironment during mammary gland development and breast cancer
NJ Brady, P Chuntova, KL Schwertfeger - Mediators of inflammation, 2016 - hindawi.com
Macrophages are critical mediators of inflammation and important regulators of developmental
processes. As a key phagocytic cell type, macrophages evolved as part of the innate …
processes. As a key phagocytic cell type, macrophages evolved as part of the innate …
[HTML][HTML] Genetically engineered T-cells for malignant glioma: overcoming the barriers to effective immunotherapy
Malignant gliomas carry a dismal prognosis. Conventional treatment using chemo- and
radiotherapy has limited efficacy with adverse events. Therapy with genetically engineered T-…
radiotherapy has limited efficacy with adverse events. Therapy with genetically engineered T-…
Novel and shared neoantigen derived from histone 3 variant H3. 3K27M mutation for glioma T cell therapy
…, S Liu, Y Lin, C Lagisetti, P Chuntova… - Journal of Experimental …, 2018 - rupress.org
The median overall survival for children with diffuse intrinsic pontine glioma (DIPG) is less
than one year. The majority of diffuse midline gliomas, including more than 70% of DIPGs, …
than one year. The majority of diffuse midline gliomas, including more than 70% of DIPGs, …
[HTML][HTML] Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma
…, LK McHenry, NM Nasholm, P Chuntova… - … for immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Background Glioblastoma (GBM) is refractory to immune checkpoint inhibitor (ICI) therapy.
We sought to determine to what extent this immune evasion is due to intrinsic properties of the …
We sought to determine to what extent this immune evasion is due to intrinsic properties of the …
JAK/STAT inhibition in macrophages promotes therapeutic resistance by inducing expression of protumorigenic factors
…, CM Lassiter, NJ Brady, P Chuntova… - Proceedings of the …, 2019 - National Acad Sciences
Tumor-associated macrophages contribute to tumor progression and therapeutic resistance
in breast cancer. Within the tumor microenvironment, tumor-derived factors activate …
in breast cancer. Within the tumor microenvironment, tumor-derived factors activate …
Activation of the FGFR–STAT3 pathway in breast cancer cells induces a hyaluronan-rich microenvironment that licenses tumor formation
LR Bohrer, P Chuntova, LK Bade, TC Beadnell… - Cancer research, 2014 - AACR
Aberrant activation of fibroblast growth factor receptors (FGFR) contributes to breast cancer
growth, progression, and therapeutic resistance. Because of the complex nature of the FGF/…
growth, progression, and therapeutic resistance. Because of the complex nature of the FGF/…
The FGF/FGF receptor axis as a therapeutic target in breast cancer
NJ Brady, P Chuntova, LK Bade… - Expert review of …, 2013 - Taylor & Francis
FGF receptor (FGFR) signaling is a vital component of both embryonic and postnatal mammary
gland development, which has prompted researchers to investigate both its relevance to …
gland development, which has prompted researchers to investigate both its relevance to …
[HTML][HTML] Inhibition of D-2HG leads to upregulation of a proinflammatory gene signature in a novel HLA-A2/HLA-DR1 transgenic mouse model of IDH1R132H …
Original research: Inhibition of D-2HG leads to upregulation of a proinflammatory gene
signature in a novel HLA-A2/HLA-DR1 transgenic mouse model of IDH1R132H-expressing …
signature in a novel HLA-A2/HLA-DR1 transgenic mouse model of IDH1R132H-expressing …
[HTML][HTML] Epiregulin contributes to breast tumorigenesis through regulating matrix metalloproteinase 1 and promoting cell survival
M Farooqui, LR Bohrer, NJ Brady, P Chuntova… - Molecular cancer, 2015 - Springer
Background The epidermal growth factor (EGF) family of ligands has been implicated in
promoting breast cancer initiation, growth and progression. The contributions of EGF family …
promoting breast cancer initiation, growth and progression. The contributions of EGF family …